title: Drug-coated balloon angioplasty for drug-eluting stent restenosis: insight from randomized controlled trials.
abstract: BACKGROUND
  The best treatment option for drug-eluting stent (DES) restenosis has not been established. We performed a meta-analysis to assess the clinical efficacy of drug-coated balloon (DCB) for the treatment of DES restenosis.
  
  
  METHODS
  Trials were identified through a literature search from January 2005 through April 2014. All randomized controlled trials were eligible for inclusion if they compared DCB with a control treatment (plain old balloon angioplasty [POBA] or DES) in patients with DES restenosis.
  
  
  RESULTS
  Five studies and a total of 864 patients were included in this analysis. Most end-points were significantly reduced for DCB compared with the control groups. For major adverse cardiac events, the relative risk (RR) was 0.49 (P = 0.012); for target lesion revascularization, it was 0.50 (P = 0.044); for recurrent restenosis, it was 0.41 (P = 0.002). There was a lower mortality for DCB (RR 0.29; P = 0.017). The incidence of myocardial infarction was numerically lower, but without statistical significance (RR 0.76; P = 0.55). The DCB effect was more pronounced when compared with POBA than when compared with DES.
  
  
  CONCLUSIONS
  This meta-analysis showed that DCB was superior to POBA and comparable to DES for treatment of DES restenosis. The findings in this meta-analysis cannot be extrapolated to DCB in general, because all DCB used in trials included was a single brand of paclitaxel-coated balloon.
authors.affiliation: Department of Cardiology, Kashgar Prefecture Second People's Hospital , Kashi, Xinjiang 844000 , China.
authors.forename: Wahafu
authors.initials: W
authors.lastname: Mamuti
authors.forename: Abulimiti
authors.initials: A
authors.lastname: Jiamali
authors.forename: Fang
authors.initials: F
authors.lastname: Rao
authors.forename: Wei
authors.initials: W
authors.lastname: Zhang
authors.forename: Xiaoli
authors.initials: X
authors.lastname: Pei
authors.forename: Alimjan
authors.initials: A
authors.lastname: Ablimit
authors.forename: Wumaierjiang
authors.initials: W
authors.lastname: Kelimu
authors.forename: Feng
authors.initials: F
authors.lastname: Zhang
mesh_terms: D015906:Angioplasty, Balloon, Coronary / Q000009:adverse effects / Q000295:instrumentation*; D023903:Coronary Restenosis / Q000628:therapy*; D054855:Drug-Eluting Stents; D006801:Humans; D015994:Incidence; D009026:Mortality; D009203:Myocardial Infarction / Q000453:epidemiology* / Q000517:prevention & control; D009204:Myocardial Revascularization; D017239:Paclitaxel / Q000008:administration & dosage; D016032:Randomized Controlled Trials as Topic; D050257:Tubulin Modulators / Q000008:administration & dosage
chemical_list: D050257:Tubulin Modulators; D017239:Paclitaxel
keywords: Drug-coated balloon; drug-eluting stent; in-stent restenosis